Skip to content

Evaluation of the Medical Service by Socio-aesthetics in Oncology

Evaluation of the Medical Service by Socio-aesthetics in Oncology

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06035731
Acronym
RCT-SE
Enrollment
400
Registered
2023-09-13
Start date
2024-05-15
Completion date
2026-06-08
Last updated
2026-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety Depression, Cancer, Breast, Cancer, Lung, Cancer of Colon, Cancer Pain, Cancer Prostate

Keywords

SOCIO-AESTHETIC

Brief summary

the 3-year randomized controlled RCT-SE study aims to investigate Socio-aesthetics well being care on quality of life, pain and anxiety. The primary objective is to show that socio-aesthetics well being care improves quality of life during cancer treatment, compared to self care administration of dermo-cosmetics products The secondary objectives are to show that socio-aesthetics well being care significantly reduced anxiety and pain compared to self care administration of dermo-cosmetics products

Detailed description

Socio-aesthetics care is the delivery appropriate beauty care in a population weakened by a physical, psychological and/or social attack. this well-being care is imperfectly assessed with few data from randomized controlled trials. The RCT-STudy is a randomized, controlled, multicenter, open label, intervention study that will be conducted among 400 patients treated with chemotherapy for breast, prostate, colon and lung cancer. Patients will be randomly assigned to one of the two arms of the study according to a 1:1 ratio: * Group A will benefit from 4 sessions of well being care performed by a qualified socio-aesthetic person, with dermo-cosmetics product defined, during 4 consecutive chemotherapy administrations . * Group B (control) will apply the same dermo-cosmetics products themselves (self-care) without intervention of socio-aesthetic, during 4 consecutive chemotherapy administrations 12 Evaluations will be conducted between chemotherapy cure N° 2 and chemotherapy cure N°5: * Pain assessed by Eva * Anxiety assessed by HADS * impact of socio-aesthetics care care , assessed by Patient Centricity Questionnaire (PCQ) (0 -110) Data will be recorded using an e-CRF. patient will be recruited over 3 years and will be followed up for 3 months. Hypothesis: Socio-aesthetics session significantly improves quality of life and reduced pain and anxiety compared to self care administration of dermo-cosmetics products

Interventions

OTHERSOCIO-AESTHETICS care

SOCIO-AESTHETICS well being care performed by qualify person

Sponsors

Centre Hospitalier de Valence
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

open label, randomized, controlled, multicenter intervention study

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* over 18 years old * treated with chemotherapy for lung , breast, colon or prostate cancer * Able to understand, read, and write French, * Affiliated with a social security scheme, * Having dated and signed an informed consent.

Exclusion criteria

* Unable to be followed for medical, social, family, geographic or psychological reasons for the duration of the study, * Deprived of their liberty by court or administrative decision,

Design outcomes

Primary

MeasureTime frameDescription
Patient Centricity Questionnaire (PCQ): Patient reported outcome: impact of supportive careup to 12 weeksPatient Centricity Questionnaire (PCQ): (0-110) higher scores mean better outcome

Secondary

MeasureTime frameDescription
pain EVAup to 12 weeksEVA (0-10) higher scores mean worse outcome.
Anxietyup to 12 weeksHADS: Hospital Anxiety and Depression Scale (0-42) higher scores mean worse outcome.

Countries

France

Contacts

PRINCIPAL_INVESTIGATORGuillaume Guillaume

CH VALENCE

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 12, 2026